Drug intelligence / Profile preview

KLR003

Development stage: Phase 1
Lead developer: Klear Bio
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

KLR003 (also known as KLR-003) is a novel therapeutic monoclonal antibody candidate being developed by Klear Bio for the treatment of psoriasis and other immune-mediated inflammatory diseases. The drug is designed to target key inflammatory and immunological pathways, though its specific molecular target remains undisclosed. KLR003 is currently undergoing Phase 1 clinical evaluation in healthy volunteers and patients with immune-mediated diseases, with early-stage clinical trials initiated in the Netherlands and the United Kingdom.

Targets

TYK2 (Tyrosine kinase 2)

Beyond the preview

Go deeper on KLR003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KLR003.